However, sICAM-1, as a competitive inhibitor of ICAM-1, can competitively bind to the LFA-1 ligand, inhibit the formation of the ICAM-1/LFA-1 complex, weaken its killing effect, and cause tumor cells to evade the body’s immune surveillance (Dustin et al., 1986; Nasu et al., 1997; Li and Gao, 2008), resulting in tumor development and metastasis. The gene discussed is ICAM1; the disease is neoplasm.